Polycystic Ovary Syndrome and Sex Hormones in Bariatric Surgery Candidates

被引：0
作者：
Dong, Shiliang [1 ]
Law, Saikam [2 ]
Ou, Changrui [3 ]
Wu, Bian [4 ]
Dong, Zhiyong [1 ]
Yang, Wah [1 ]
Zhang, Xiaoguan [1 ,5 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Metab & Bariatr Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gastrointestinal Surg, Guangzhou, Peoples R China
[3] Southern Med Univ, Sch Publ Hlth, Guangzhou, Peoples R China
[4] Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Dept Gen Surg, Affiliated Hosp, 157 Jingbi Rd, Kunming 650032, Yunnan, Peoples R China
[5] Dalang Hosp, Dept Gen Surg, Dongguan, Guangdong, Peoples R China
来源：
OBESITY SURGERY | 2025年 / 35卷 / 03期
关键词：
Polycystic ovary syndrome; Obesity; Sex hormones; BMI; Testosterone; INSULIN-RESISTANCE; SYNDROME PCOS; METABOLIC SYNDROME; PREVALENCE; OBESITY; WOMEN; OVERWEIGHT; CRITERIA; RATIO;
D O I：
10.1007/s11695-025-07740-9
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Background Polycystic ovary syndrome (PCOS) is a prevalent metabolic and endocrine disorder affecting women of reproductive age, particularly those with obesity. This syndrome is characterized by clinical/biochemical hyperandrogenism and/or ovulatory dysfunction, which can result in infertility. Purpose To investigate the prevalence of PCOS in candidates for bariatric surgery and to examine the correlation between PCOS and sex hormones in women with obesity. Methods A retrospective study analyzed 577 bariatric surgery candidates from 2015 to 2021 using RStudio. Normally distributed data were expressed as x +/- s and compared with ANOVA or T-test, while the Kruskal-Wallis test was used for non-normal data. Count data, presented as M [Q1, Q3], were analyzed with the Chi-square test. Logistic regression identified influencing factors, with P < 0.05 indicating statistical significance. Results The findings of our study reveal that the prevalence of PCOS among bariatric surgery candidates stands at 14.04%. Conversely, high-density lipoprotein cholesterol (HDL-C) levels tended to decrease with higher BMI categories (P = 0.02). Compared to the non-PCOS group, the PCOS group exhibits lower age and HDL-C levels. Still, they showed significantly elevated HOMA-IR, fasting blood glucose (FBG), luteinizing hormone (LH), total testosterone (TT), and luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratio (P < 0.05). The logistic regression analysis of PCOS indicates that, compared to the control group, those with FBG levels exceeding 7 mmol/L (OR = 2.28, 95% CI 1.19 to 4.37, P = 0.01) and individuals with TT levels greater than 2.01 ng/ml (OR = 2.36, 95% CI 1.23 to 4.71, P = 0.01) exhibited an increased risk of PCOS. Conclusion PCOS is highly prevalent among female bariatric surgery candidates. It is significantly associated with younger age, lower HDL, higher FBG, and elevated TT levels. These factors may also serve as indicators for evaluating PCOS improvement and assessing surgical outcomes postoperatively.
引用
收藏
页码：984 / 991
页数：8
相关论文
共 62 条
  • [51] Cadagan D., Khan R., Amer S., Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome, Reprod Biol, 16, pp. 53-60, (2016)
  • [52] Gu Y., Xu W., Zhuang B., Fu W., Role of A-kinase anchoring protein 95 in the regulation of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) in human ovarian granulosa cells, Reprod Fertil Dev, 30, pp. 1128-1136, (2018)
  • [53] Wekker V., van Dammen L., Koning A., Et al., Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis, Hum Reprod Update, 26, pp. 942-960, (2020)
  • [54] Zhang C., Li Y., Wang Y., Et al., Genetic associations of metabolic factors and therapeutic drug targets with polycystic ovary syndrome, J Adv Res, (2024)
  • [55] Kulkarni S., Gupta K., Ratre P., Et al., Polycystic ovary syndrome: current scenario and future insights, Drug Discov Today, 28, (2023)
  • [56] Wang J., Yin T., Liu S., Dysregulation of immune response in PCOS organ system, Front Immunol, 14, (2023)
  • [57] Helvaci N., Yildiz B.O., Polycystic ovary syndrome and aging: health implications after menopause, Maturitas, 139, pp. 12-19, (2020)
  • [58] Ji S., Yang H., Ji Y., Et al., Liraglutide improves PCOS symptoms in rats by targeting FDX1, Reprod Sci, 31, pp. 2049-2058, (2024)
  • [59] Sun S., Liu Y., Li L., Et al., Unveiling the shared genetic architecture between testosterone and polycystic ovary syndrome, Sci Rep, 14, (2024)
  • [60] Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., Escobar-Morreale H.F., A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 7, pp. 2434-2438, (2000)
1234567